Trianglerelugolix + ARPI (NCT07216248)
relugolix + ARPI trial for Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (NCT07216248). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with metastatic hormone-sensitive prostate adenocarcinoma, without small-cell histology. A smartphone is required.
The idea: relugolix reduces testosterone, alongside an androgen-pathway inhibitor. Cohort A responders reaching PSA at most 0.2 nanograms/milliliter after six to twelve months enter random assignment to continuous or intermittent treatment. Cohort B patients already meeting that PSA threshold after hormone therapy receive intermittent treatment. Researchers assess fatigue and progression-free survival in the respective cohorts.
This phase 2 study plans 160 patients. Utah sponsors it; Huntsman, Salt Lake City, is the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.